Phage susceptibility testing methods or 'phagograms': where do we stand and where should we go?

被引:1
|
作者
Kolenda, Camille [1 ,2 ]
Jourdan, Julie [1 ]
Roussel-Gaillard, Tiphaine [1 ]
Medina, Mathieu [1 ,2 ]
Laurent, Frederic [1 ,2 ]
机构
[1] Hosp Civils Lyon, Inst Agents Infect, Serv bacteriol, Lyon, France
[2] Univ Claude Bernard Lyon 1, Univ Lyon, CIRI Ctr Int Rech Infectiol, Team StaPath,Inserm,U1111,CNRS,UMR5308,ENS Lyon, Lyon, France
关键词
BACTERIOPHAGE THERAPY; EFFICACY;
D O I
10.1093/jac/dkae325
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Phage therapy is a highly promising approach to address the challenge that is presented by the global burden of antimicrobial resistance. Given the natural specificity of phages, phage susceptibility testing (PST) is a prerequisite for successful personalized therapy, allowing the selection of active phages from large and diverse collections. However, the issue of an easy-to-use and standardized technique remains. In this review, we describe the principles, advantages and drawbacks of two routinely used PST techniques: plaque and growth kinetic assays. These are labour-intensive and time-consuming methods that require automation of one or more steps, including preparation of test panels, incubation, reading and analysis of results. In addition to automation, there is an urgent need to establish a reference method to enable efficient of PST techniques selection of therapeutic phages. We discuss knowledge gaps and parameters that need to be investigated to work towards this goal.
引用
收藏
页码:2742 / 2749
页数:8
相关论文
共 50 条
  • [21] Where do we stand on neuroprotection? Where do we go from here?
    Shoulson, I
    MOVEMENT DISORDERS, 1998, 13 : 46 - 48
  • [22] THE CYTOGENETICS OF RENAL TUMORS - WHERE DO WE STAND, WHERE DO WE GO
    WALTER, TA
    BERGER, CS
    SANDBERG, AA
    CANCER GENETICS AND CYTOGENETICS, 1989, 43 (01) : 15 - 34
  • [23] THE DECADE OF TOTAL QUALITY - WHERE DO WE STAND - WHERE DO WE GO
    YEAGER, R
    PIMA MAGAZINE, 1994, 76 (03): : S2 - S3
  • [24] Occupational Rhinitis and Asthma: Where Do We Stand, Where Do We Go?
    Castano, Roberto
    Malo, Jean-Luc
    CURRENT ALLERGY AND ASTHMA REPORTS, 2010, 10 (02) : 135 - 142
  • [25] RED ALGAL SPECIES: WHERE DO WE STAND, WHERE DO WE GO?
    Zuccarello, G. C.
    PHYCOLOGIA, 2013, 52 (04) : 127 - 128
  • [26] Breast Cancer in India: Where Do We Stand and Where Do We Go?
    Khokhar, Anita
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (10) : 4861 - 4866
  • [27] Household stockholding in Europe: where do we stand and where do we go?
    Guiso, L
    Haliassos, M
    Jappelli, T
    Claessens, S
    ECONOMIC POLICY, 2003, (36) : 123 - 170
  • [28] Occupational Rhinitis and Asthma: Where Do We Stand, Where Do We Go?
    Roberto Castano
    Jean-Luc Malo
    Current Allergy and Asthma Reports, 2010, 10 : 135 - 142
  • [29] Mesenchymal Stromal Cells' Therapy for Polyglutamine Disorders: Where Do We Stand and Where Should We Go?
    Barros, Ines
    Marcelo, Adriana
    Silva, Teresa P.
    Barata, Joao
    Rufino-Ramos, David
    Pereira de Almeida, Luis
    Miranda, Catarina O.
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2020, 14
  • [30] Organoids, Where We Stand and Where We Go
    Don, Flaminia Kaluthantrige
    Huch, Meritxell
    TRENDS IN MOLECULAR MEDICINE, 2021, 27 (05) : 416 - 418